IP Library › Granted Patent US 12,214,035
Granted Patent B2
US 12,214,035 · App. 17/576,021 · Granted Feb 4, 2025

Herpesvirus compositions and related methods

Inventors: Stephen Anderson (Cambridge, MA); Simon Delagrave (Cambridge, MA); John Hamberger (Milford, NH); Qinglian Li (Aurora, CA); Sophia Mundle (Cambridge, MA); Nausheen Rahman (Toronto, CA)
Assignees: SANOFI PASTEUR LIMITED; SANOFI PASTEUR INC.
A61K39/245A61K9/0019A61K39/12A61K47/183A61K47/26C12N7/00A61K2039/5254C12N2710/16034C12N2710/16611C12N2710/16634C12N2710/16651
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,214,035
App. No.
17/576,021
Granted
Feb 4, 2025
Kind
B2
Abstract

The present disclosure relates to liquid and dried compositions comprising a live, attenuated or genetically modified herpesvirus and methods of preparing such compositions, in one aspect, the composition comprises at least two or more pharmaceutically acceptable excepients, at least one of which is histidine and at least one of which is a sugar or sugar alcohol. The compostions retain a sufficiently high infectious titre following storage or large-scale manufacturing steps, such as lyophilization.

Claims (29)

1. A method of manufacturing a dried composition comprising a live, attenuated or genetically modified herpesvirus, the method comprising:

(i) admixing the live, attenuated or genetically modified herpesvirus with histidine or glutamine and sucrose or trehalose; and

(ii) drying the admixture, to form a dried composition, wherein the dried composition consists of:

a live, attenuated or genetically modified herpes simplex virus type-2 (HSV-2) or herpes simplex virus type-1 (HSV-1),

1 mM to 50 mM histidine or glutamine,

sucrose or trehalose,

sodium chloride, and

glutamate, and has a pH of about 6.5 to 7.5.

2. The method of claim 1 , wherein the admixture is dried by means of a method selected from the group consisting of freeze-drying, foam-drying, and spray-drying.

3. The method of claim 1 , wherein the HSV-2 or the HSV-1 is a replication-defective herpes simplex virus.

4. The method of claim 1 , wherein viral titres of the live, attenuated or genetically modified herpesvirus are between 10 7 to 10 5 pfu/mL before drying.

5. The method of claim 1 , wherein the glutamate is selected from the group consisting of potassium glutamate, mono sodium glutamate, and sodium glutamate.

6. The method of claim 1 , wherein the glutamate is present in an amount of 1 mM to 100 mM.

7. The method of claim 1 , wherein the histidine is present in an amount of 5 mM to 20 mM and the sucrose is present in an amount of 5% to 10% w/v.

8. The method of claim 1 , wherein the glutamate is selected from the group consisting of 1 mM to 100 mM potassium glutamate, 1 mM to 100 mM mono sodium glutamate, and 1 mM to 100 mM sodium glutamate.

9. The method of claim 1 , wherein the live, attenuated or genetically modified herpesvirus is a HSV-2.

10. The method of claim 9 , wherein the HSV-2 is a replication defective HSV-529 strain.

11. The method of claim 1 , wherein the HSV-1 or HSV-2 contains less than 10 ng of host cell DNA per 1×10 7 pfu/mL.

12. The method of claim 1 , wherein the residual moisture content of the dried composition is 6% or less.

13. The method of claim 1 , wherein the histidine is present in an amount of 5 mM to 20 mM histidine, the sucrose is present in an amount of 5% to 10% w/v, and the glutamate comprises potassium glutamate and the potassium glutamate is present in an amount of 25 mM to 75 mM.

14. The method of claim 13 , wherein the sodium chloride is present in an amount of 80 to 160 mM.

15. The method of claim 1 , wherein the sodium chloride is present in an amount of 10 to 200 mM.

16. A method of manufacturing a dried composition comprising a live, attenuated or genetically modified herpesvirus, the method comprising:

(i) admixing the live, attenuated or genetically modified herpesvirus with histidine, sucrose or trehalose, sodium chloride, and glutamate; and

(ii) drying the admixture, wherein the dried composition consists of:

a live, attenuated or genetically modified herpes simplex virus type-2 (HSV-2) or herpes simplex virus type-1 (HSV-1),

about 10 mM 1 mM,

about 10% w/v sucrose or trehalose, sodium chloride, and

about 50 mM glutamate, and has a pH of about 6.5 to 7.5.

Assignments (3)
MERGER Recorded Jul 13, 2022
From: SANOFI PASTEUR BIOLOGICS, LLC
To: SANOFI PASTEUR INC.
Reel/Frame 060498/0841 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2022
From: MUNDLE, SOPHIA; DELAGRAVE, SIMON; ANDERSON, STEPHEN; HAMBERGER, JOHN
To: SANOFI PASTEUR BIOLOGICS, LLC.
Reel/Frame 058658/0589 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2022
From: LI, QINGLIAN; RAHMAN, NAUSHEEN
To: SANOFI PASTEUR LIMITED
Reel/Frame 058658/0716 →
Continuity (4)
Division 14402678
Provisional Application 61649884 · May 21, 2012
Provisional Application 61792913 · Mar 15, 2013
Related Publication 20220133881A1 · May 5, 2022
References Cited (59)
US 4337242A · Markus et al. · 1982 [cited by applicant]
US 4338335A · McAleer et al. · 1982 [cited by applicant]
US 4500512A · Barme · 1985 [cited by applicant]
US 5024836A · McAleer et al. · 1991 [cited by applicant]
US 6251678B1 · Volkin et al. · 2001 [cited by applicant]
US 6258362B1 · Loudon et al. · 2001 [cited by applicant]
US 6267958B1 · Andya · 2001 [cited by examiner]
US 6267967B1 · Johnston et al. · 2001 [cited by applicant]
US 8084039B2 · Stinchcomb et al. · 2011 [cited by applicant]
US 8501194B2 · Spector et al. · 2013 [cited by applicant]
US 8877492B2 · Delagrave et al. · 2014 [cited by applicant]
US 9132184B2 · Vellom et al. · 2015 [cited by applicant]
US 9365832B2 · Mundle et al. · 2016 [cited by applicant]
US 10363304B2 · Mundle et al. · 2019 [cited by applicant]
US 20060141483A1 · Calton · 2006 [cited by examiner]
US 20080248551A1 · Stinchcomb et al. · 2008 [cited by applicant]
US 20080286850A1 · Liu et al. · 2008 [cited by applicant]
US 20090325284A1 · Truran et al. · 2009 [cited by applicant]
US 20100008944A1 · Knipe et al. · 2010 [cited by applicant]
US 20100015180A1 · Francon et al. · 2010 [cited by applicant]
US 20100247573A1 · Vellom et al. · 2010 [cited by applicant]
US 20110201087A1 · Delagrave et al. · 2011 [cited by applicant]
US 20160331832A1 · Mundle et al. · 2016 [cited by applicant]
EP 0008255 · 1980 [cited by applicant]
EP 0028563 · 1981 [cited by applicant]
EP 0252059 · 1998 [cited by applicant]
EP 2280064A2 · 2011 [cited by applicant]
WO 9945104A2 · 1999 [cited by applicant]
WO 9955348 · 1999 [cited by applicant]
WO 2004112707A2 · 2004 [cited by applicant]
WO 2008057550A2 · 2008 [cited by applicant]
WO 2013095965A1 · 2013 [cited by applicant]
International Search Report dated Oct. 24, 2013 from International Application No. PCT/US2013/42039, pp. 1-12. [cited by applicant]
Hansen, Raino K. et al. Mechanisms of Inactivation of HSV-2 during Storage in Frozen and Lyophilized Forms. Biotechnol. Prog., 2005(21): 911-917. [cited by applicant]
Zhai, Suling et al. Effect of Freezing Rates and Excipients on the Infectivity of a Live Viral Vaccine during Lyophilization. Biotechnol. Prog., 2004(20): 1113-1120. [cited by applicant]
Extended European Search Report dated Dec. 16, 2015 for International Application No. EP13793902, 9 pages. [cited by applicant]
Apte et al., “Effect of Buffers and Stabilizers on Vaccine Stability and Efficacy”, Development of Vaccines, Jan. 1, 2011, vol. 8, pp. 399-414. [cited by applicant]
Abdul-Fattah et al., “Drying-Induced Variations in Physico-Chemical Properties of Amorphous Pharmaceuticals and Their Impact on Stability II: Stability of a Vaccine”, Pharmaceutical Research, Feb. 15, 2007, vol. 24, No.… [cited by applicant]
Chen et al., “Opportunities and challenges of developing thermostable vaccines”, Expert Review of Vaccines, May 1, 2009, vol. 8, No. 5, pp. 547-557. [cited by applicant]
Hansen et al., “Mechanisms of Inactivation of HSV-2 during Storage in Frozen and Lyophilized Forms”, Biotechnology Progress, Sep. 5, 2005, vol. 21, No. 3, pp. 911-917. [cited by applicant]
Communication pursuant to Article 94(3) EPC from European Patent Office dated Sep. 28, 2017 for European Application No. EP13793902.1, 7 pages. [cited by applicant]
International Search Report and Written Opinion dated Mar. 11, 2013 from International Application No. PCT/US2013/020780 (Authorized Officer, Lee W. Young), 7 pages. [cited by applicant]
Supplementary Partial European Search Report, issued Apr. 15, 2015 from corresponding European Application No. 13735764.6, 5 pages. [cited by applicant]
Hoshino, et al., “Protection from Herpes Simplex Virus (HSV)-2 Infection with Replication-Defective HSV-2 or Glycoprotein D2 Vaccines in HSV-1-Seropositive and HSV-1-Seronegative Guinea Pigs,” J. Infectious Dis., vol. 2… [cited by applicant]
Mundle, et al., “High-Purity Preparation of HSV-2 Vaccine Candidate ACAM529 Is Immunogenic and Efficacious In Vivo,” PLOS One, vol. 8, issue 2, Feb. 2013, e57224, pp. 1-10. [cited by applicant]
O'Keeffe, et al., “The Affinity Adsorptive Recovery of an Infectious Herpes Simplex Virus Vaccine,” Biotechnology and Bioengineering, vol. 62, No. 5, Mar. 5, 1999, pp. 537-545. [cited by applicant]
Kyle Grant, “Production and Purification of Highly Replication Defective HSV-1 Based Gene Therapy Vectors”, Doctoral Dissertation, University of Pittsburgh, published through the online, D-scholarship@Pitt repository in… [cited by applicant]
Extended European Search Report (includes European Search Report and European Search Opinion), dated Oct. 19, 2017 for European Patent Application No. 17178956.3, 8 pages. [cited by applicant]
Jenson et al., “Comparison of various transport media for viability maintenance of herpes simplex virus, respiratory syncytial virus, and adenovirus”, Diagnostic Microbiology and Infectious Disease, Jul. 1, 1994, vol. 1… [cited by applicant]
Mundle et al., “Preparation of pure, high titer, pseudoinfectious Flavivirus particles by hollow fiber tangential flow filtration and anion exchange chromatography”, Vaccine, Dec. 1, 2014, vol. xxx, pp. 1-6. [cited by applicant]
Final Office Action dated Mar. 27, 2018 for U.S. Appl. No. 15/155,951, 5 pages. [cited by applicant]
Non-Final Office Action dated Nov. 3, 2017 for U.S. Appl. No. 15/155,951, 6 pages. [cited by applicant]
Non-Final Office Action dated Aug. 14, 2015 for U.S. Appl. No. 14/369,844, 11 pages. [cited by applicant]
Brandau et al., “Thermal Stability of Vaccines”, Journal of Pharmaceutical Sciences, 2003, vol. 92, vol. 2, pp. 218-231. [cited by applicant]
Frank Kofi Bedu-Addo, “Understanding Lyophilization Formulation Development”, Pharmaceutical Technology, Lyophilization, 2004, pp. 20-18. [cited by applicant]
Da Costa et al., “Construction, Phenotypic Analysis, and Immunogenicity of a UL5/UL29 Double Deletion Mutant of Herpes Simplex Virus 2”, Journal of Virology, 2000, vol. 74, No. 17, pp. 7963-7971. [cited by applicant]
Non-Final Office Action dated May 12, 2021 for U.S. Appl. No. 16/505,168, 12 pages. [cited by applicant]
Knop et al., “Bioreactor Production of Recombinant Herpes Simplex Virus Vectors”, Biotechnology Progress, 2007, vol. 23, No. 3, pp. 715-721. [cited by applicant]
Zhu et al., “Mixed matrix membranes decorated with, In situ self-assembled polymeric nanoparticles driven by electrostatic interaction”, Journal of Materials Chemistry, 2018, vol. 6, pp. 7859-7870. [cited by applicant]